Acute Coronary Syndrome Market
Market Overview
Between 2023 and 2030, the Acute Coronary Syndrome Market is expected to grow significantly. The market will grow at a CAGR of 5.2% from 2023 to 2030, to reach USD 14,810.38 million by 2030, according to Pharmanucleus. An increase in the incidence of chronic diseases such as coronary heart disease, ischemic heart disease, and vascular disease, growing geriatric population, and diverse product offering by market players are the major drivers for the growth of the coronary syndrome market acute.
Market Analysis and Insights
Acute coronary syndrome refers to a group of diseases in which blood flow to the heart decreases. Conditions related to ACS include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. It is a type of coronary heart disease (CHD), responsible for a third of the total number of deaths in people over 35 years of age. Some forms of coronary artery disease can be asymptomatic, but ACS is always symptomatic.
Acute coronary syndrome (ACS) is a manifestation of coronary heart disease (CHD) and usually results from a rupture of plaque in the coronary arteries (atherosclerosis). Common risk factors for the disease are smoking, hypertension, diabetes, hyperlipidemia, physical inactivity, family obesity and poor nutritional practices. Cocaine abuse can also lead to vasospasm. A family history of early myocardial infarction (55 years) is also a high risk factor.
Global Acute Coronary Syndrome Market report provides details about market share, new developments, impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in regulation market trends, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and market scenario, contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Market Dynamics
Drivers
- Rise in Prevalence of Chronic Diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases
As companies are constantly engaged in research and development activities, knowledge about the prevalence of chronic heart and vascular diseases would help to find new solutions, and the development of cardiology and vascular devices would contribute to more collaborations and partnerships with market players in the United States. , Europe and Asia-Pacific. This means that the increase in research and development investments for the discovery and development of treatments for acute coronary syndrome is driving the growth of the market.
- Growing Geriatric Population
The number of elderly people declaring respective cardiovascular diseases is high. For this reason, the ever-increasing geriatric population which is expected to grow in the coming years globally, primarily in the Middle East, Africa, and Asia-Pacific region, is expected to create an opportunity for market growth. during the forecast period.
- Wide Range of Products Offered by Market Players
Strategic product launches and collaborations made by leading companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions. This strategy allows companies to strengthen their footprint in the market. Therefore, the strategic initiative is expected to be the golden opportunity for market players to accelerate their revenue growth in the market.
Opportunities
- Surge in Technological Advancements for Cardiovascular Disease
As technology advances rapidly, it improves the way cardiovascular disease is managed. Additionally, recent healthcare monitoring apps and gadgets have improved the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the global acute coronary syndrome market during the forecast period.
Also, Governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.
Restraints/Challenges
Rising cost of therapeutic surgery and lack of accessibility of disease management and support services in low economy countries are the restraints and challenges for the growth of the acute coronary syndrome market.
The increased complexity and cost of cardiology equipment and strong investments would increase costs. Rising cost would lead to delayed treatment of patients in hospitals and clinics and clearance of these products is very stringent and time consuming, many products struggle to get approved due to non-compliance with regulations which can hamper market growth.
This Acute Coronary Syndrome Market report provides details about recent new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of national and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic analysis of market growth, market size, category market growth, niches and dominance applications, product approvals, product launches, geographic expansions, technological innovations in the market. For more insights on the Acute Coronary Syndrome Market, contact Pharmanucleus for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Post COVID Impact
The Acute Coronary Syndrome (ACS) market has experienced significant impacts as a result of the COVID-19 pandemic. ACS refers to a group of conditions characterized by reduced blood flow to the heart, including unstable angina and myocardial infarction (heart attack).
During the pandemic, healthcare systems worldwide faced overwhelming pressures due to the influx of COVID-19 patients. This led to a shift in resources, including healthcare professionals, hospital beds, and medical equipment, towards managing COVID-19 cases. As a result, the diagnosis, treatment, and management of ACS patients were affected, leading to delayed or suboptimal care for many individuals.
Furthermore, fear of contracting the virus and restrictions on movement and healthcare access resulted in a decrease in ACS patient visits to hospitals and clinics. Many patients either postponed seeking medical attention or opted for telemedicine consultations, which may not have been as effective in evaluating and treating ACS cases.
The pharmaceutical industry faced challenges in conducting clinical trials and launching new therapies for ACS due to disruptions in research activities and regulatory processes. Additionally, supply chain disruptions and manufacturing delays impacted the availability of medications and medical devices used in the management of ACS.
As the world gradually recovers from the pandemic, efforts are being made to address the impact on ACS patients. Healthcare systems are working to restore regular ACS care, including improving access to diagnostic tests, implementing telemedicine solutions, and prioritizing ACS patients for timely interventions. The pharmaceutical industry is also adapting and resuming research and development activities to bring innovative treatments to the market.
While the full extent of the long-term impact of the COVID-19 pandemic on the ACS market remains to be seen, concerted efforts are underway to mitigate the challenges and ensure improved care for individuals with ACS.
Recent Development
Merck's acquisition of Acceleron Pharma Inc. in November 2021 is a significant milestone for the company. The acquisition represents a critical and strategic opportunity for Merck to expand its cardiovascular portfolio and pipeline. Merck has a long and proud history in the field of cardiovascular disease, and this acquisition further strengthens its position in the market.
By acquiring Acceleron Pharma Inc., Merck gains access to Acceleron'sgroundbreaking research in the cardiovascular field. This research has the potential to fuel Merck's business development strategy and enhance its capabilities in developing innovative therapies for cardiovascular diseases.
The acquisition allows Merck to tap into the expertise and resources of Acceleron Pharma Inc., which has a strong reputation for its research and development efforts. This partnership will enable Merck to accelerate the development of new treatments, explore novel therapeutic approaches, and address unmet needs in the field of cardiovascular disease.
Expanding its cardiovascular portfolio aligns with Merck's commitment to improving patient outcomes and addressing the growing burden of cardiovascular diseases globally. By combining their strengths and resources, Merck and Acceleron Pharma Inc. can work synergistically to advance the field of cardiovascular medicine and bring innovative therapies to patients.
Market Scope
The worldwide acute coronary syndrome market is divided into four categories: type, therapy, diagnostic, and end user. Growth in these categories will assist you in analysing important growth segments across industries and providing users with useful market information and industry insights to make strategic decisions to find major market applications.
Type
- Non-St-Elevation Myocardial Infarction
- St-Elevation Myocardial Infarction
- Unstable Angina
On the basis of type, the global acute coronary syndrome market is segmented into non-St-elevation myocardial infarction, St-elevation myocardial infarction and unstable angina.
Diagnosis
- Stress Test
- Blood Tests
- Imaging
- Others
On the basis of diagnosis, the global acute coronary syndrome market is segmented into stress test, blood test, imagining and others.
Treatment
- Medication
- Surgery
On the basis of treatment, the global acute coronary syndrome market is segmented into medication and surgery.
End User
- Hospitals and Clinics
- Diagnostic Centers
- Academic Institutes
- Others
On the basis of end user, the global acute coronary syndrome market is segmented into hospitals and clinics, diagnostic centers, academic institutes and others.
Acute Coronary Syndrome Market Regional Analysis/Insights
The global acute coronary syndrome market is further segmented into major countries including US, Canada & Mexico North America, Germany, France, UK, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey and rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines and rest from Asia-Pacific, South Africa, Saudi Arabia, United Arab Emirates, Egypt, Israel and rest of Middle East and Africa, Brazil, Argentina and rest of South America.
North America dominates the global acute coronary heart disease market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. The United States dominates due to the presence of major market players who provide the vast drug portfolio and well-developed healthcare infrastructure in this region, while Germany dominates due to the flexible range of choice of services and wide coverage of the population. China dominates due to the growing pool of patients, especially the exponentially growing geriatric population.
The country section of the report also provides individual factors impacting the market and regulatory changes in the market that impact current and future market trends. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major indicators used to forecast the market scenario for each country. In addition, the presence and availability of global brands and the challenges they face due to strong competition from local and national brands, as well as the impact of sales channels are considered while providing forecast analysis of national data.
Competitive Landscape and Global Acute Coronary Syndrome Market Share Analysis
Global Acute Coronary Syndrome Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, research and development investment, new market initiatives, production sites and facilities , company strengths and weaknesses, product launch, product testing pipelines, product approvals, patents, product breadth and scope, application dominance, technology lifeline curve . The data points above provided are only related to the companies focus on the Acute Coronary Syndrome market.
The major prominent participants operating in the global acute coronary syndrome market are Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), MYODERM (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) and others.